New combo therapy aims to shrink multiple colorectal tumors before surgery
NCT ID NCT06002789
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a PD-1 monoclonal antibody (immunotherapy) alone or combined with chemotherapy (mFOLFOX6) before surgery in people with multiple colorectal cancers. The goal is to shrink tumors and increase the chance of complete removal while preserving organs. The study enrolls 17 participants with specific genetic markers (dMMR/MSI-H).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1 monoclonal antibody (immunotherapy) and mFOLFOX6 chemotherapy
- What this could lead to
- If successful, this could offer a personalized treatment approach for people with multiple colorectal cancers, potentially reducing the need for extensive surgery and preserving more healthy tissue.
- What could go wrong
- This is a small, early-phase study with only 17 participants, so results may not apply to everyone. Immunotherapy and chemotherapy can cause serious side effects, and the treatment may not work for all tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sixth Affiliated Hospital, Sun Yatsen University
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?